Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates,Arthur Kavanaugh,Philip J. Mease,Enrique R. Soriano,Maria Laura Acosta-Felquer,April W. Armstrong,Wilson Bautista-Molano,Wolf-Henning Boehncke,Willemina Campbell,Alberto Cauli,Luis R. Espinoza,Oliver FitzGerald,Dafna D. Gladman,Alice B. Gottlieb,Philip S. Helliwell,M. Elaine Husni,Thorvardur Jon Love,Ennio Lubrano,Neil McHugh,Peter Nash,Alexis Ogdie,Ana Maria Orbai,Andrew Parkinson,Denis O'Sullivan,Cheryl F. Rosen,Sergio Schwartzman,Evan L. Siegel,Sergio Toloza,William Tuong,Christopher T. Ritchlin +29 more
TLDR
To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).Abstract:
Objective
To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).
Methods
GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire.
Results
Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema.
Conclusion
We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.read more
Citations
More filters
Journal ArticleDOI
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec,Xenofon Baraliakos,Andreas Kerschbaumer,Maarten de Wit,Iain B. McInnes,Maxime Dougados,Jette Primdahl,Dennis McGonagle,Daniel Aletaha,Andra Balanescu,Peter V. Balint,Heidi Bertheussen,Wolf-Henning Boehncke,Gerd R Burmester,Juan D. Cañete,Nemanja Damjanov,Tue Wenzel Kragstrup,Tore K Kvien,Robert Landewé,Rik Lories,Helena Marzo-Ortega,Denis Poddubnyy,Santiago Rodrigues Manica,Georg Schett,Douglas J. Veale,Filip Van den Bosch,Désirée van der Heijde,Josef S Smolen +27 more
TL;DR: The updated recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.
Journal ArticleDOI
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen,Monika Schöls,Jürgen Braun,Maxime Dougados,Oliver FitzGerald,Dafna D. Gladman,Arthur Kavanaugh,Robert Landewé,Philip J. Mease,Joachim Sieper,Tanja Stamm,Maarten de Wit,Daniel Aletaha,Xenofon Baraliakos,Neil Betteridge,Filip Van den Bosch,Laura C. Coates,Paul Emery,Lianne S. Gensler,Laure Gossec,Philip S. Helliwell,Merryn Jongkees,Tore K Kvien,Robert D. Inman,Iain B. McInnes,Mara Maccarone,Pedro Machado,Anna Molto,Alexis Ogdie,Denis Poddubnyy,Christopher T. Ritchlin,Martin Rudwaleit,Adrian Tanew,Bing Thio,Douglas J. Veale,Kurt de Vlam,Désirée van der Heijde +36 more
TL;DR: There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA.
Journal ArticleDOI
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip J. Mease,Stephen Hall,Oliver FitzGerald,Désirée van der Heijde,Joseph F. Merola,Francisco Avila-Zapata,Dorota Cieślak,Daniela Graham,Cunshan Wang,Sujatha Menon,Thijs Hendrikx,Keith S. Kanik +11 more
TL;DR: The efficacy of tofacitinib was superior to that of placebo at month 3 in patients with psoriatic arthritis who had previously had an inadequate response to conventional synthetic DMARDs.
Journal ArticleDOI
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna D. Gladman,William F. C. Rigby,Valderílio Feijó Azevedo,Frank Behrens,Ricardo Blanco,Andrzej Kaszuba,Kudlacz Elizabeth M,Cunshan Wang,Sujatha Menon,Thijs Hendrikx,Keith S. Kanik +10 more
TL;DR: In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 months in reducing disease activity.
Journal ArticleDOI
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A. Singh,Gordon H. Guyatt,Alexis Ogdie,Dafna D. Gladman,Chad L. Deal,Atul Deodhar,Maureen Dubreuil,Jonathan Dunham,M. Elaine Husni,Sarah Kenny,Jennifer Kwan-Morley,Janice Lin,Paula Marchetta,Philip J. Mease,Joseph F. Merola,Julie Miner,Christopher T. Ritchlin,Bernadette C. Siaton,Benjamin J Smith,Abby S. Van Voorhees,Anna Helena Jonsson,Amit Aakash Shah,Nancy Sullivan,Marat Turgunbaev,Laura C. Coates,Alice B. Gottlieb,Marina Magrey,W. Benjamin Nowell,Ana Maria Orbai,Soumya M. Reddy,Jose U. Scher,Evan Siegel,Michael Siegel,Jessica A. Walsh,Amy S. Turner,James Reston +35 more
TL;DR: The 2018 ACR/NPF guideline as mentioned in this paper provides evidence-based guidelines for the pharmacologic and non-pharmacologic treatment of psoriatic arthritis (PsA) using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology.
References
More filters
Journal ArticleDOI
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
William J. Taylor,Dafna D. Gladman,Philip S. Helliwell,Antonio Marchesoni,Philip J. Mease,Herman Mielants +5 more
TL;DR: The CASPAR criteria are simple and highly specific but less sensitive than the Vasey and Espinoza criteria and are confirmed as the validity of clinical diagnosis as the gold standard definition of "case"-ness.
Journal ArticleDOI
Treatment recommendations for psoriatic arthritis
Christopher T. Ritchlin,Arthur Kavanaugh,Dafna D. Gladman,Philip J. Mease,Philip S. Helliwell,Wolf-Henning Boehncke,K. de Vlam,David Fiorentino,Oliver FitzGerald,Alice B. Gottlieb,Neil McHugh,Peter Nash,Abrar A. Qureshi,Enrique R. Soriano,William J. Taylor +14 more
TL;DR: Treatment recommendations for the cardinal physical manifestations of PsA were developed based on a literature review and consensus between rheumatologists and dermatologists and a grid was established to assist in therapeutic reasoning and decision making for individual patients.
Journal ArticleDOI
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes,Philip J. Mease,Bruce Kirkham,Arthur Kavanaugh,Christopher T. Ritchlin,Proton Rahman,Désirée van der Heijde,Robert Landewé,Philip G. Conaghan,Alice B. Gottlieb,Hanno B. Richards,Luminita Pricop,Gregory Ligozio,Manmath Patekar,Shephard Mpofu +14 more
TL;DR: Subcutaneous secukinumab 300 mg and 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secuk inumab is a potential future treatment option for patients with this disorder.
Journal ArticleDOI
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,Lluís Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Y. Wang,Alan M. Mendelsohn,Mittie K. Doyle +10 more
TL;DR: Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments.
Journal ArticleDOI
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten,Xenofon Baraliakos,Jürgen Braun,Joachim Sieper,Paul Emery,Désirée van der Heijde,Iain B. McInnes,Jacob M van Laar,Robert Landewé,Paul Wordsworth,Paul Wordsworth,Jürgen Wollenhaupt,Herbert Kellner,Jacqueline E Paramarta,Jiawei Wei,Arndt Brachat,Stephan Bek,Didier Laurent,Yali Li,Ying A Wang,Arthur P. Bertolino,Sandro Gsteiger,Andrew M Wright,Wolfgang Hueber +23 more
TL;DR: Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated, making it the first targeted therapy that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial.
Related Papers (5)
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Laure Gossec,Josef S Smolen,Sofia Ramiro,M. de Wit,Maurizio Cutolo,Maxime Dougados,Paul Emery,Robert Landewé,Sue Oliver,Daniel Aletaha,Neil Betteridge,Jürgen Braun,G.-R. Burmester,Juan D. Cañete,Nemanja Damjanov,Oliver FitzGerald,Emma Haglund,P S Helliwell,Tore K Kvien,Rik Lories,Thomas A. Luger,Mara Maccarone,Helena Marzo-Ortega,Dennis McGonagle,Iain B. McInnes,I. Olivieri,Karel Pavelka,Georg Schett,Joachim Sieper,F. Van den Bosch,Douglas J. Veale,Jürgen Wollenhaupt,Angela Zink,D. van der Heijde +33 more